{"prompt": "['55', 'Each AE will be independently judged by the investigator in terms of causality. The following', 'definitions will be used for these causality assessments.', 'Related:', 'This causal relationship is assigned when the AE:', 'starts a reasonable time after study device administration,', \"cannot be reasonably explained by the subject's clinical state.\", 'Possibly Related:', 'This causal relationship is assigned when the AE:', 'starts a reasonable time after study device administration, but', \"could have been produced by the subject's clinical state or other\", 'modes of therapy administered to the subject.', 'Unrelated:', 'This causal relationship is assigned when the AE:', 'is definitely not associated with the study device administered', 'and is readily explained by other events or diagnoses.', 'Each AE will also be independently judged by the investigator in terms of severity. The following', 'definitions will be used for these severity assessments.', 'Mild:', 'The event is transient (<48 hours) or causes mild discomfort; no', 'medical intervention/therapy is required', 'Moderate:', 'The event results in mild to moderate limitation in activity - some', 'assistance may be needed; no or minimal medical', 'intervention/therapy is required', 'Severe:', 'The event results in marked limitation in activity, assistance is', 'usually required; medical intervention/therapy is required and', 'hospitalization is possible', 'Each AE will also be independently judged by the investigator in terms of seriousness. A serious', 'adverse event (SAE) is defined as any untoward medical occurrence that:', 'Results in death, or', 'Is life-threatening,', 'Note: The term \"life-threatening\" in the definition of \"serious\" refers to an event in', 'which the subject was at risk of death at the time of the event; it does not refer to an', 'event which hypothetically might have caused death if it were more severe.', 'Requires inpatient hospitalization or prolongation of existing hospitalization,', 'Results in permanent impairment of a body function or permanent damage to a body', 'structure,', 'Is a congenital anomaly/birth defect,', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']['56', 'Necessitates medical or surgical intervention to preclude any one of the outcomes', 'listed in this definition.', 'All SAEs must be reported immediately (within 24 hours of knowledge of the event) by telephone', 'and fax to the study manager:', 'FAX: 480-907-1292', 'Attention: Medical Monitor', 'The investigator will follow up with a written description of the SAE submitted to the sponsor', 'within 3 days, including the results of the SAE investigation and any treatment(s) provided.', \"All adverse events will be followed until resolution or until the investigator assesses the subject's\", 'status has returned to normal.', '11.2', 'Anticipated Adverse Device Effects Associated with Provant Therapy System', 'Anticipated adverse events associated with PROVANTR Therapy System are as follows:', 'Skin Reaction in the application area (i.e. rash, erythema)', 'Altered sensation in the treatment area (i.e. burning, paresthesia)', 'Hyperalgesia in the application area (i.e. increased pain, hypersensitivity)', '11.3', 'Unanticipated Adverse Device Effect (UADE)', 'Unanticipated Adverse Device Effect means any serious adverse effect on health or safety or any', 'life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or', 'death was not previously identified in nature, severity, or degree of incidence in the protocol or', 'informed consent form, or any other unanticipated serious problem associated with the device that', 'relates to the rights, safety, or welfare of subjects. The protocol will contain all of the anticipated', 'Adverse Events that could be associated with the study.', 'All UADEs must be reported immediately (within 24 hours of knowledge of the event) by telephone', 'and fax to the following:', 'Regenesis Biomedical, Inc. Fax: (480) 907-1292The investigator will follow up with a written', 'description of the UADE submitted to the sponsor within 3 days, including the results of the UADE', 'investigation and any treatment(s) provided.', 'Any UADE occurring up to the date of the final Follow-up Visit will be followed until it resolves,', \"the investigator assesses the subject's status to have returned to baseline, or until the investigator\", 'feels that the event is stable and chronic.', 'The investigator shall submit to the reviewing IRB a report of any UADE occurring during an', 'investigation as soon as possible in accordance with the IRB submission guidelines, but in no event', 'later than 10 working days after the investigator first learns of the effect.', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}